2-TUR QANDLI DIABET BILAN KASALLANGAN BEMORLARDA KOGNITIV FUNKSIYAGA SGLT2 INGIBITORLARINING TA’SIRI
##article.subject##:
SGLT2i, 2-tur qandli diabet, kognitiv buzilishlar (KB), demensiya, neyroproteksiya##article.abstract##
tur qandli diabet (QD2) kognitiv buzilishlar, jumladan demensiya rivojlanish xavfining ortishi bilan So‘nggi yillarda natriy-glyukoza kotransporteri 2-tur (SGLT2i) ingibitorlari ehtimoliy neyroprotektiv ta’sirga ega bo‘lgan antidiabetik preparatlar sifatida mashhurlikka ega bo‘ldi. SGLT2i ingibitorlari yurak va buyrak faoliyatini yaxshilashdan tashqari, kognitiv buzilishlarni (KB) — jumladan, yengil kognitiv buzilish, Altsgeymer kasalligi va tomirli demensiyani — oldini olish va davolashda ham muhim ijobiy ta’sir ko‘rsatishi mumkin. Tadqiqotlar shuni ko‘rsatadiki, SGLT2i preparatlari diabet bilan bog‘liq kognitiv buzilishlarni metabolik yo‘llar, yallig‘lanish, oksidlovchi stress, neyrotrofik omillar va atsetilxolinesteraza (AHE) ni ingibitsiyalash orqali yaxshilashi mumkin. Ushbu maqola QD2 bilan kasallangan bemorlarda SGLT2 ingibitorlarining kognitiv funksiyaga ta’siri bo‘yicha mavjud ma’lumotlar tahliliga bag‘ishlangan. Adabiyotlar tahlili ushbu preparatlarning neyrodegeneratsiya xavfini kamaytirish va kognitiv holatni barqarorlashtirishdagi salohiyatini ko‘rsatadi, biroq bu borada qo‘shimcha keng ko‘lamli klinik tadqiqotlar o‘tkazilishi zarur.
Библиографические ссылки
Biessels G.J., Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604.
Cherney D.Z.I., Cooper M.E. The role of SGLT2 inhibitors in modifying neurocognitive decline in diabetes. Diabetologia. 2020;63(11):2246– 2250.
Tanaka A. et al. SGLT2 inhibitors and risk of dementia in patients with type 2 diabetes: A real-world data analysis. Diabetes Care. 2023;46(2):348–355.
Kodl C.T., Seaquist E.R. Cognitive dysfunction and diabetes mellitus. Endocr Rev. 2008;29(4):494–511.
Vallon V., Thomson S.C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–225.
Rosenstock J. et al. Effects of empagliflozin on brain health: subanalysis of a randomized clinical trial. Lancet Neurology. 2021;20(5):389–397.
Garcia-Ropero A. et al. Cognitive benefits of dapagliflozin in elderly patients with type 2 diabetes and cardiovascular risk. Front Aging Neurosci. 2022;14:813345.
Sachdev P.S., Blacker D., Blazer D.G., Ganguli M., Jeste D.V., Paulsen J.S., Petersen R.C. Classifying neurocognitive disorders: The DSM-5 approach. Nat. Rev. Neurol. 2014;10:634–642. doi: 10.1038/nrneurol.2014.181.
Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., Breteler M.M. Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia. 1996;39:1392–1397.
Mukadam N., Wolters F.J., Walsh S., Wallace L., Brayne C., Matthews F.E., Sacuiu S., Skoog I., Seshadri S., Beiser A., et al. Changes in prevalence and incidence of dementia and risk factors for dementia: An analysis from cohort studies. Lancet Public Health. 2024;9:e443–e460.
Chekol Tassew W., Ferede Y.A., Zeleke A.M. Cognitive impairment and associated factors among patients with diabetes mellitus in Africa: A systematic review and meta-analysis. Front. Endocrinol. 2024;15:1386600.
Kuate Defo A., Bakula V., Pisaturo A., Labos C., Wing S.S., Daskalopoulou S.S. Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis. Diabetes Obes. Metab. 2024;26:441–462.
Chen Q., Zhu S., Shang J., Fang Q., Xue Q., Hua J. Trends in Cognitive Function Before and After Diabetes Onset: The China Health and Retirement Longitudinal Study. Neurology. 2024;102:e209165.
